NCT00470704: Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 2 prior chemotherapy regimens for the treatment of advanced breast cancer; Patients with prior treatment of lapatinib or other HER2-directed therapy except for Herceptin/trastuzumab; Patients with active brain metastases

Comments are closed.

Up ↑